Progestin Primed Ovarian Stimulation (PPOS) protocol yields lower euploidy rate in older patients undergoing IVF

• Published in: Reproductive biology and endocrinology Vol. 21; no. 1; p. 72
• Main Authors: Pai, Angel Hsin-Yu, Sung, Yen Ju, Li, Chia-Jung, Lin, Chieh- Yu, Chang, Chia Lin
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 08.08.2023; BioMed Central; BMC
• Subjects: Age; Aged patients; Aging; Analysis; Aneuploidy; Biopsy; Birth rate; Body mass index; Care and treatment; Clinical outcomes; Embryos; Euploidy rate; Fertility; Fertilization; Fertilization in vitro; Genetic screening; GnRH-antagonist; Gonadotropin-releasing hormone; Gonadotropins; Health aspects; Implantation; In vitro fertilization; Infertility; Measurement; Menstruation; Miscarriage; Ovaries; Patient outcomes; Patients; Pituitary (anterior); Pituitary hormones; Pregnancy; Preimplantation genetic testing for aneuploidy (PGT-a); Progestin; Progestin-primed ovarian stimulation (PPOS); Reproductive technologies; Taiwan; Switzerland; Germany; Euploidy rate; Preimplantation genetic testing for aneuploidy (PGT-a); GnRH-antagonist; Progestin-primed ovarian stimulation (PPOS)
• ISSN: 1477-7827; 1477-7827
• DOI: 10.1186/s12958-023-01124-3

To explore if exogenous progestin required for progestin primed ovarian stimulation (PPOS) protocol compromises the euploidy rate of patients who underwent preimplantation genetic testing cycles when compared to those who received the conventional gonadotropin-releasing hormone (GnRH) antagonist protocol. This retrospective cohort study analyzed 128 preimplantation genetic testing for aneuploidy (PGT-A) cycles performed from January 2018 to December 2021 in a single university hospital-affiliated fertility center. Infertile women aged 27 to 45 years old requiring PGT-A underwent either PPOS protocol or GnRH-antagonist protocol with in-vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) for fertilization. Frozen embryo transfers were performed following each PGT-A cycle. Data regarding the two groups were analyzed using the Statistical Package for Social Sciences (SPSS) version 22.0 (SPSS Inc., Chicago, IL). Patients who underwent PPOS treatment had significantly reduced blastocyst formation rate and euploidy rate compared to those who received the GnRH antagonist protocol. Subgroup-analysis was performed by stratifying patients' age into elder and young subgroups (elder: ≥ 38-year-old, young: < 38-year-old). In the elder sub-population, the blastocyst formation rate of the PPOS group was significantly lower than that of the GnRH-antagonist group (45.8 ± 6.1% vs. 59.9 ± 3.8%, p = 0.036). Moreover, the euploidy rate of the PPOS group was only about 20% of that of  the GnRH-antagonist group (5.4% and 26.7%, p = 0.006). In contrast, no significant differences in blastocyst formation rate (63.5 ± 5.7% vs. 67.1 ± 3.2%, p = 0.45) or euploidy rate (30.1% vs. 38.5%, p = 0.221) were observed in the young sub-population. Secondary outcomes, which included implantation rate, biochemical pregnancy rate, clinical pregnancy rate, live birth rate, and miscarriage rate, were comparable between the two treatment groups, regardless of age. When compared to the conventional GnRH-antagonist approach, PPOS protocol could potentially reduce the euploidy rate in aging IVF patients. However, due to the retrospective nature of this study, the results are to be interpreted with caution. Before the PPOS protocol is widely implemented, further studies exploring its efficacy in larger populations are needed to define the optimal patient selection suitable for this method. Human Investigation and Ethical Committee of Chang Gung Medical Foundation (202200194B0).